Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes! here it is on TD Ameritrade!!
$IMUN @ImmuneLDN
— DazeTrader (@DazeTrader) September 5, 2018
Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry. By GlobeNewswire pic.twitter.com/ytbfRxrwWi
ones who believe in the company should be loading their boats today. last week Friday (2 trading days ago) it looked like we were about to pop through $0.02
GlobeNewswire-PR: Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry https://on.mktw.net/2oLmMON $IMUN
September 5, 2018 - 11:15 AM EDT
Print
Email Article
Font Down
Font Up
Charts
IMUN 0.0172 0.0001
Today 5d 1m 3m 1y 5y 10y
Immune Therapeutics Labeled as a Pioneer in Forbes Article Discussing Booming Pet Care Industry
ORLANDO, Fla., Sept. 05, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE - - Immune Therapeutics, Inc. (OTCQB: IMUN), a late stage biopharmaceutical company focused on the development of therapies for the treatment of autoimmune diseases, inflammatory diseases, cancer and HIV/AIDS, today announced that the Company’s multi-pronged growth strategy, which includes the pursuit of the multi-billion dollar pet care industry, was favorably mentioned in an article published today in Forbes Magazine. (Link to Story: Can Cats and Dogs Help Reverse Marijuana’s Stigma?)
The article, which also includes excerpts from an interview with the Company’s CEO, Noreen Griffin, classifies Immune Therapeutics as a ‘pioneering biopharmaceutical company that recognized the massive potential in the growing animal health market and has introduced a partnership to tap into it’ (referring to the Company’s recent 10% acquisition of Cytocom, Inc. which included exclusive rights to Lodonal™ and Met-Enkephline for the treatment of pets in the United States).
“Today’s positive coverage of Immune Therapeutics by such a well-respected and internationally distributed publication, such as Forbes, is a yet another indication that Immune has truly embarked on a new era of growth and expansion as we look towards the bright future that lays ahead,” said Ms. Griffin. “We believe the ongoing progress we are making in Africa, along with the recent filings of new patents and the exclusive revenue channels stemming from the pet care industry will further strengthen Immune Therapeutics, Inc.’s market position,” concluded Ms. Griffin.
Immune Therapeutics Gains Exclusive Drug Rights for Booming Pet Care Industry
The global market for animal medication is projected to reach $44.4 billion by 2022, driven by increasing investments in animal drug development in response to unmet animal health needs and developments in veterinary diagnostics and services. Overall, 68% of U.S. households, or about 84.6 million homes, own a pet, according to the APPA. Dogs and cats are the most popular pets, followed by freshwater fish and birds.
ABOUT IMMUNE THERAPEUTICS, INC.
Immune Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of highly innovative immunotherapies. Immune Therapeutics is actively developing T-Activation immunotherapies to achieve immunomodulation in patients both human and pets with autoimmune and inflammatory disease, cancer and infectious diseases.
Forward-Looking Statements
This release may contain forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all the matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company’s filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company’s filings with the Securities and Exchange Commission (www.sec.gov), including its recent periodic reports.
888-613-8802
http://www.immunetherapeutics.com/
IMUN logo.png
Source: GlobeNewswire (September 5, 2018 - 11:15 AM EDT)
News by QuoteMedia
What exactly do you like about the SS? Thanks
Yes. Article covering Immune Therapeutics, Inc. 4D cancer treatment protocols. https://sciencetrends.com/the-plan-of-four-dimensional-regulation-4d-plan-for-cancer-patients-first-systematic-plan-for-cancer-patients-in-the-world/
Article covering Immune Therapeutics, Inc. 4D cancer treatment protocols https://t.co/fOy3E0zHFU
— Immune Therapeutics (@ImmuneLDN) August 30, 2018
When does otc season usually start and finish?
8-K from Aug 21 2018.
https://www.otcmarkets.com/filing/html?id=12927884&guid=WyoEUn10eYWKw3h
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 16, 2018
INNOCAP, INC.
(Exact name of registrant as specified in its charter)
Nevada
333-153035
01–0721929
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification Number)
112 N. Walnut Street
PO Box 489
Jefferson, TX 75657-0489
(Address of principal executive offices) (zip code)
770-378-4180
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General InstructionA.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 OTHER EVENTS.
In November 2017, Innocap entered into an agreement with Solar Resources Inc. (“Solar”), a company in Singapore, to assist Solar to recover large shipments of tin from two sunken ships that are believed to be in the waters between Singapore, the Philippines, Indonesia and Malaysia.
The salvage ship was fully equipped at the end of May 2018. After leaving the harbor in Singapore to commence the salvage recovery effort, the ship’s equipment experienced unexpected mechanical problems that required it to return to harbor for repairs. Shortly after the repairs were completed, the seas in the area were hit with severe storms which limited the salvage ship’s ability to reach the salvage area and required it to refuel in Malaysia.
The salvage ship is now in the area of the seas outside the Philippines where one of the sunken ships is believed to be located.
No assurances can be given that the sunken ship will be found or that its contents will be consistent with reports describing such contents.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, Innocap, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 20, 2018
/s/ Paul Tidwell
Paul Tidwell
Chief Executive Officer
Interesting find, I like the fact that the twitter account that posted it is located in the Canadian province of Alberta *hint hint*.
Here is the twitter link for everyone to see, follow the breadcrumbs, etc.
#DYK @alrtechnologies provides remote monitoring for diabetes patients with a unique, FDA-cleared software platform. The platform helps health care providers optimize a patient's insulin therapy and improve health outcomes. https://t.co/0Ijx6ELgYI #BioAlbertaMember #abbiz
— BioAlberta (@Bioalberta) June 19, 2018
The $IMUN company has a twitter page and they started tweeting again in Aug 2018! They are paying attention :)
Renown HIV specialist Dr. Gary Blick Joins Immune Therapeutics Advisory Boardhttps://t.co/h0yUapUPzk #Lodonal #IMUN $IMUN #LDN
— Immune Therapeutics (@ImmuneLDN) August 23, 2018
even so, i'd imagine the prop group who bought ~10M+ shares today around ~.0018 will want to sell it at a higher price.
News.coming? someone probably knows something, buyers initiated today, volume: 12.96m as of 1:54 PM EDT Aug 22, 2018
NVSOS registered agent change filed 6/18/2018
Entity Actions for "LTS NUTRACEUTICALS, INC."
Sort by descendingascending order
1 - 16 of 16 actions
Actions\Amendments
Action Type: Registered Agent Change
Document Number: 20180273472-66 # of Pages: 1
File Date: 6/18/2018 Effective Date:
(No notes for this action)
Action Type: Annual List
Document Number: 20180267130-00 # of Pages: 1
File Date: 6/13/2018 Effective Date:
(No notes for this action)
Action Type: Annual List
Document Number: 20170310668-04 # of Pages: 1
File Date: 7/21/2017 Effective Date:
(No notes for this action)
https://www.nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=Y9cAcufVLlSX4J3jOWG1hA%253d%253d&CorpName=LTS+NUTRACEUTICALS%2c+INC.
crypto stocks got momo yesterday, i was just thinking it's ready to rip.
Very interesting! Thanks for sharing. Any more updates about the company?
Folks re-read june282018 PR. The big announcement should be coming very soon. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=141879456
$LOCMQ Bankruptcy Case Closed, DISMISSED! +216%
http://bit.ly/2niJyNm
Good job $KRED on brand recognition work.
Aug 1, 2018, 09:08pm
Sam Darnold Ready To Compete For Jets Starting QB Job After Contract Impasse by J.P. Pelzman.
Teddy Bridgewater was asked eight questions during his post-practice media session Wednesday. Four were about Sam Darnold.
Josh McCown was the recipient of seven questions from reporters. Five were about Sam Darnold.
Rookie quarterback Darnold figures to be a hot topic throughout the Jets' 2018 season, which is natural considering the former collegiate star at USC was the third-overall pick, and New York is hoping he can be its franchise quarterback for a long time.
But like most athletes, Darnold wants to be the starter sooner rather than later.
"The competitor in me, yeah I want to start," Darnold told a crowd of reporters after his second training-camp practice, "but at the same time it’s about the team and whatever’s best for the team."
He later added, "I'm just going to come out here every day and practice and control what I can control and do what I can to earn my--to possibly earn that start, but at the same time just continue to get better every single day. ... With Josh and Teddy, it's a huge challenge (to start on opening day)."
The Jets begin the regular season at Detroit on Sept. 10.
Sam Darnold has 20 million reasons to smile, now that he will be getting his guaranteed money up front this month. (Photo by Mark Brown/Getty Images)
Darnold missed the first three practices of camp while his representatives and the Jets negotiated the fine print in his contract. Darnold's four-year, $30.25 deal was slotted according to his draft position, so there was no room for haggling there. But he and his management, Creative Artists Agency, wanted there to be no offset language in his contract, meaning that if he were to be released before the end of it, he could get paid by both the Jets and his new team.
https://www.forbes.com/sites/jppelzman/2018/08/01/sam-darnold-ready-to-compete-for-jets-starting-qb-job-after-contract-impasse/#47c6c7b51f28
$KRED @KonaRed Welcomes NEW Head Roaster, Cano Cardenas. http://bit.ly/2vSBNBV
More info on Cano. https://www.linkedin.com/in/cano-cardenas-56531559
$KRED KonaRed Hawaiian Coffee Announces Partnership with Professional Football Player Sam Darnold. http://bit.ly/2vHLEKA
Might have been insiders or zakeni selling cheap paper before we go zero bid.
Last call for cheap nachos!
What type of big things are coming?
Yes, quite a number of large offers are stacking up. Yes some people are looking for an exit now, they have given up on waiting and just want out and to move elsewhere. I don’t blame them at this point, we were all expecting the positive news by now. I hope the news comes soon.
3.5 Million Shares Salable Starting July 26th
When pinksheets like these get suspended by SEC, they get delisted to the graysheets and then bleed a slow death, eventually the trading volume stops and the price is at $0.0001 - $0.02
$VICT $PDXP $CYPE
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142273043
SPYR-Inc-SEC-Charges-Joe-Fiore-&-SPYR-Inc-With-Fraud
The SEC has officially accused Joe Fiore and SPYR Inc. (formerly Eat at Joe's) with FRAUD (source).
July 26, 2018 - 9:30 AM EDT
Charts
PLPL 0.0051 0.0001
SPYR 0.225 -0.0446
SPYR Inc. still has a $50 million market cap despite having only $115,000 in cash & securities remaining as of the end of Q1-2018 and a >$800,000 quarterly burn rate. Coinciding with the Fraud charges the SEC is seeking disgorgement of >$11,500,000 of profits from Joe Fiore, Joe’s fund (Berkshire Capital), and SPYR Inc. With the company itself possibly out of cash, paying the fine may be a struggle.
SPYR Inc. (formerly known as Eat at
Read more ...
https://seekingalpha.com/article/4190362-spyr-inc-sec-charges-joe-fiore-and-spyr-inc-fraud?source=quotemedia_readmore
Source: SeekingAlpha (July 26, 2018 - 9:30 AM EDT)
News by QuoteMedia
My bet is that SPYR goes to zero before one dollar.
Longs_need_to ask Joe what his agenda is.
initial SEC suspension? What happens to the stock afterwards? It gets delisted from Pinksheet and goes to greysheets to bleed out to zero.
Fridays are usually news or SEC filings, when the company has any ready to distribute.
are those YOUR 400K and 700K bids?
Massive bidders lining up! Yesterday a 3M bid size coming in at 52-wk lows, nice bottom has formed, market buyers are in the bush nearby.
screenshot here:
@DJPennyTrader 3M bid size coming in at 52-wk lows, nice bottom has formed, market buyers are in the bush nearby. INN0 pic.twitter.com/ryf9XmVRRh
— DazeTrader (@DazeTrader) July 18, 2018
Small float, nice share structure here. Company doesn't have a history of continuous reverse splits (compared to other penny stock companies that dilute their shareholders, INNO doesn't appear to be).
INNO SECURITY DETAILS
Share Structure
Market Cap
793,144
07/18/2018
Authorized Shares
199,000,000
10/31/2016
Outstanding Shares
151,075,000
06/14/2018
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
33,311,109
05/06/2016
This is the only stock split I could find for $INNO and it was back in 1998. Stock Splits: 10.00; 1:10 (09/11/1998)
news & filing will make this moonshot
Any day now....
feels like somebody knows something good is coming! :)
8K SEC Filing. News here.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): July 12, 2018
Intiva BioPharma Inc.
(Exact Name Of Registrant As Specified In Its Charter)
Commission File No.: 0-55320
Delaware 26-2049376
(State of Incorporation) (I.R.S. Employer Identification No.)
4340 E Kentucky Ave, Suite 206, Glendale, CO 80246
(Address of Principal Executive Offices) (ZIP Code)
Registrant’s Telephone Number, including area code: (303) 495-7583
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company [X]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 7.01 Regulation FD Disclosure.
On July 12, 2018, Intiva BioPharma Inc. issued a press release providing details regarding the appointment of Dr. Benedikt Schoser as an advisor to the company. A copy of the press release is included as Exhibit 99.1. This Form 8-K and the information included as exhibits shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended (“Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing. The furnishing of the information in this report is not intended to, and does not, constitute a determination or admission by the Company that the information in this report is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Registrant or any of its affiliates.
Item 9.01 Financial Statements and Exhibits.
Regulation
S-K Number
Document
99.1 Press release dated July 12, 2018
2
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTIVA BIOPHARMA INC.
/s/: Alain Bankier
Alain Bankier, Chief Executive Officer
July 12, 2018
3
EXHIBIT INDEX
Regulation
S-K Number
Document
99.1 Press release dated July 12, 2018
4
INTIVA BioPharma Retains Dr. Benedikt Schoser as an Advisor
Munich-based Dr. Schoser is a world-renowned expert on the molecular mechanisms of muscle loss and weakness, and myotonic dystrophy
Denver, Colorado, July 12, 2018 - INTIVA BioPharma Inc. (“INTIVA” or the “Company”) (OTC: NTVA) today announced that Germany-based, Dr. Benedikt Schoser has been retained as an advisor to the Company.
Dr. Schoser is the senior consultant neurologist and co-chair of the Friedrich-Baur Institute, Germany’s major national referral center for rare neuromuscular diseases. In 2016 he received an additional degree in palliative medicine. Since 2016, Dr. Schoser has served as co-chair of the Scientific Muscle and Neuromuscular panel of the European Academy of Neurology and in 2018 became a Fellow of the European Academy of Neurology. His clinical and research interests are in the field of multisystemic neuromuscular diseases and metabolic and myotonic myopathies.
Dr. Schoser is an Associated Professor of Neurology at the Ludwig Maximilians University at their campuses in both Hamburg and Munich. Since 2010 he has also been the head of the Interdisciplinary Center for Neuromuscular Disorders at the University’s Munich campus. Dr. Schoser has authored and co-authored more than 200 articles in peer reviewed journals, and contributed more than 20 chapters to books on neurology and muscle pathology, primarily focused in the field of diagnostic features and translational therapeutic trials in myotonic dystrophies, myasthenic syndromes, metabolic myopathies, and inflammatory myopathies. He serves as a member of the Editorial Board of Neuromuscular Disorders, the Journal of Neuromuscular Diseases, and Journal of Rheumatology and until February 2017 was the past chair of the Scientific Board of Neuromuscular Centers.
Rob Goldfarb, INITVA’s Chief Operating Officer stated, “We are excited that Dr. Schoser is part of our scientific team. Dr. Schoser is one of the world’s top researchers in both molecular mechanisms of muscle loss and myotonic dystrophy. Dr. Schoser’s professional focus is on the investigation of molecular mechanisms of muscle loss and weakness in patients, and most importantly, in translating research on the basic mechanism into clinical reality.” Mr. Goldfarb also stated, “Since INTIVA has a pending patent application for the use of cannabinoids and terpenes for the treatment of dystrophies and myotonia, we’re excited to benefit from Dr. Schoser’s extensive knowledge regarding myotonic dystrophy and in having his assistance advancing the Company’s pre-clinical and clinical drug development strategy for myotonia.”
About Myotonia
Myotonia refers to a neuromuscular condition in which the relaxation of a muscle is impaired and can affect any muscle group. Because a repeated effort is required to relax the muscle, individuals with myotonia may have trouble with normal activities including releasing their grip on objects and having difficulty rising from a seated position. Patients suffering from myotonia often walk with a stiff, awkward gait.
Myotonic dystrophy is a genetic disorder that affects muscular function. Symptoms include gradually worsening muscle loss and weakness. There is currently no cure for myotonic dystrophy; however, various drugs have been administered to manage symptoms without great success.
INTIVA has filed a utility patent application with the United States Patent Office relating to the use of cannabinoids to treat myotonia, myotonic dystrophy and other related dystrophies. The application claims the benefit of a provisional patent application that was filed by the Company in 2017.
About INTIVA BioPharma Inc.
INTIVA BioPharma is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration (“FDA”) pre-clinical and clinical pathways, to address a broad range of medical conditions and disorders.
INTIVA BioPharma’s drug development strategy consists of:
A. The determination of medical conditions and disorders that could potentially benefit from cannabinoid-based formulations;
B. Conducting “freedom to operate” investigations on these conditions;
C. The preparation of patent applications and the prosecution of such application and/or the licensing of existing patents;
D. Identifying the regulatory pathway with the FDA; and
E. Proceeding with pre-clinical and clinical development activities in accordance with FDA protocols for submission to obtain approval for the particular product(s).
INTIVA BioPharma website: www.intivabiopharma.com .
INTIVA Disclosure Notice: This press release contains “forward-looking statements. For this purpose, any statements contained herein or which are otherwise made by or on behalf of INTIVA BioPharma that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; INTIVA BioPharma’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of INTIVA BioPharma’s control.
Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. INTIVA BioPharma undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.
Company Contact:
Mark Lubchenco
Director of Investor Relations
INTIVA BioPharma Inc.
Tel. 1-303-495-7583
Email mlubchenco@intivabiopharma.com
Website www.INTIVABioPharma.com
https://backend.otcmarkets.com/otcapi/company/sec-filings/12857635/content/html
News! Findit Continues to Innovate with the Upcoming Rollout for Podcasts and Interviews for Members Press Release | 07/10/2018 http://bit.ly/2L6Tjsp
$FDIT 3M float size, 96% of O/S held tight. #10bagger http://bit.ly/2ozTFi2
Buying opportunity at $2.00 today, cheapies! Due to some twitter postings regarding "short sellers", there are cheap shares available today in the open market at $2.00. People that are shorting $NTVA at $2.00 are likely gonna be hurting in the very near future.
There is currently 6 different twitter accounts re-posting this same message about NTVA short sellers. They are trying to create some fear in this stock, no idea why though! That twitter poster is wrong about $NTVA
The twitter poster appears to own all 6 different twitter accounts and all the websites that it is linking to. This looks like a Internet SEO person who makes money selling affiliate links to trade-ideas.com market scanner. THIS TWITTER POSTER HAS NO IDEA ABOUT ANYTHING TO DO WITH $NTVA -- DO NOT BELIEVE WHAT HE IS POSTING ABOUT!
Bibey Post
@bibeypost_stock
3h3 hours ago
More
What's Next for INTIVA BIOPHARMA INC $NTVA After Having More Shares Shorted? -
REurope
@reurope_stock
3h3 hours ago
More
Time to Reconsider INTIVA BIOPHARMA INC $NTVA After More Short Sellers?
?
@mmahotstuff1
3h3 hours ago
More
It Seems INTIVA BIOPHARMA INC $NTVA Will Go Down. Just Reported More Shorted Shares -
@whatsonthorold2
3h3 hours ago
More
What's Next for INTIVA BIOPHARMA INC $NTVA After Having More Shares Shorted? -
@west_moreland
3h3 hours ago
More
Could INTIVA BIOPHARMA INC $NTVA Skyrocket? The Stock Has Too Many Sellers
@Fanob_stock
3h3 hours ago
More
INTIVA BIOPHARMA INC $NTVA Stock Is Shorted More
https://twitter.com/bibeypost_stock/status/1016670015142187010
Time to Reconsider INTIVA BIOPHARMA INC $NTVA After More Short Sellers? https://t.co/s76NyipIH8
— REurope (@reurope_stock) July 10, 2018
It Seems INTIVA BIOPHARMA INC $NTVA Will Go Down. Just Reported More Shorted Shares - https://t.co/24etR65E7I
— Money Making Articles Hot Stuff (@mmahotstuff1) July 10, 2018
What's Next for INTIVA BIOPHARMA INC $NTVA After Having More Shares Shorted? - https://t.co/kAqEYhh2fy
— WhatsOnThorold (@whatsonthorold2) July 10, 2018
Could INTIVA BIOPHARMA INC $NTVA Skyrocket? The Stock Has Too Many Sellers https://t.co/EvGXTmqmt8
— Westmoreland Times (@west_moreland) July 10, 2018